AlzeCure Publishes its Interim Report for January - September 2025

STOCKHOLM, SE / ACCESS Newswire / November 11, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - September 2025 is now available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/

"The third quarter of 2025 was an active and eventful quarter for AlzeCure Pharma. In July, we received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for our pain drug Painless ACD440 for the rare disease erythromelalgia. Furthermore, we carried out a rights issue of SEK 48.5 million, with an overallotment option of SEK 10 million. The rights issue was backed by all major shareholders, as well as by the company's Board of Directors and management group through subscription commitments. The rights issue was oversubscribed to 212% and generated total proceeds of SEK 58.5 million. We are very pleased and proud of this strong outcome and wish to thank all participants in the rights issue for their confidence in the plans on which the issue was based. We also presented and published new data for our pain projects ACD440 and TrkA-NAM. During the quarter, we further strengthened our organization by appointing Dr. Cecilia Wadell as Head of Development. She brings extensive experience in AlzeCure's therapeutic areas and will be responsible for leading our development efforts."

Martin Jönsson, CEO

Financial information for July - September 2025, Group
Figures in parentheses refer to the corresponding period of the previous year.

• Net sales during the period totaled SEK 0 thousand (0).

• Earnings for the period totaled SEK -10,025 thousand (-7,474).

• Earnings per share, basic, totaled SEK -0.09 (-0.09).

• Cash flow from operating activities totaled SEK -7,619 thousand (SEK -8,067).

• Total assets at the end of the period amounted to SEK 66,591 thousand (47,554).

• Cash and cash equivalents at the end of the period totaled SEK 59,190 thousand (39,187).

Financial information for January - September 2025, Group
Figures in parentheses refer to the corresponding period of the previous year.

• Net sales during the period totaled SEK 0 thousand (0).

• Earnings for the period totaled SEK -29,912 thousand (-25,994).

• Earnings per share, basic, totaled SEK -0.31 (-0.35).

• Cash flow from operating activities totaled SEK -26,012 thousand (SEK -26,819).